9 jan 2023
JPMorgan presentation
Potential for indication expansion: Literature reports of CAIX expression
Glioblastoma Multiforme
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Gastric Cancer
Pancreatic Ductal Adenocarcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Cholangio-carcinoma
Soft Tissue Sarcoma
Epithelial Ovarian Cancer
Colorectal Cancer
- Forums
- ASX - By Stock
- TLX
- Ann: Phase II study for indication expansion of TLX250-CDx doses
Ann: Phase II study for indication expansion of TLX250-CDx doses, page-7
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.55 |
Change
-0.450(2.50%) |
Mkt cap ! $5.872B |
Open | High | Low | Value | Volume |
$17.90 | $17.95 | $17.42 | $21.96M | 1.248M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 17117 | $17.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.57 | 2880 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 9791 | 17.540 |
1 | 3048 | 17.510 |
1 | 500 | 17.500 |
1 | 50 | 17.470 |
1 | 20 | 17.460 |
Price($) | Vol. | No. |
---|---|---|
17.570 | 2880 | 1 |
17.600 | 4130 | 2 |
17.620 | 2880 | 1 |
17.650 | 2880 | 2 |
17.660 | 2571 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online